IP Library Granted Patent US 8,398,967
Granted Patent B2
US 8,398,967 · App. 13/091,970 · Granted Mar 19, 2013

Particle formulations for use in pharmaceutical compositions

Inventors: Rom Ezer Eliaz (San Rafael, CA); Yuanpeng Zhang (Cupertino, CA); Catherine Manya Rohloff (Los Altos, CA); Eric William Weeks (Hayward, CA); Gunjan Junnarkar (Palo Alto, CA)
Assignee: Intarcia Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,398,967
App. No.
13/091,970
Granted
Mar 19, 2013
Kind
B2
Abstract

A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Claims (25)

1. A particle formulation for use in a pharmaceutical composition comprising a protein or peptide, sucrose, methionine, and citrate buffer.

2. The particle formulation of claim 1 , wherein said protein or peptide is selected from the group consisting of interferon, erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor, human growth hormone releasing hormone, insulin, infliximab, and glucagon-like peptide-1.

3. The particle formulation of claim 2 , wherein the protein or peptide is glucagon-like peptide-1.

4. The particle formulation of claim 2 , wherein the protein or peptide is an interferon.

5. The particle formulation of claim 4 , wherein the interferon is selected from the group consisting of omega-interferon, alpha-interferon, beta-interferon, and gamma-interferon.

6. The particle formulation of claim 1 , wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15.

7. The particle formulation of claim 1 , wherein particles of the formulation are made by spray-drying, lyophilization, or supercritical fluid processing.

8. The particle formulation of claim 1 , wherein the particle formulation comprises spray-dried particles.

9. The particle formulation of claim 8 , wherein the spray-dried particles comprise particles of about 1 μm to about 10 μm in diameter.

10. An implantable osmotic delivery device, comprising:

a capsule having a first chamber containing a viscous liquid pharmaceutical composition and a second chamber containing an osmotic agent, the first chamber having an opening through which the pharmaceutical composition can be delivered from the first chamber to a location external of the first chamber;

a movable piston positioned in the capsule between the first chamber and the second chamber;

a wall of the second chamber comprising a fluid permeable membrane portion;

and an incompressible fluid additive located within the second chamber and substantially surrounding the osmotic agent;

wherein the viscous liquid pharmaceutical composition comprises the particle formulation of claim 1 dispersed in a suspending vehicle, and the suspending vehicle comprising a solvent selected from the group consisting of benzyl benzoate, lauryl lactate, and lauryl alcohol.

11. The implantable osmotic delivery device of claim 10 , wherein the solvent is benzyl benzoate.

12. The implantable osmotic delivery device of claim 10 , wherein the solvent is lauryl lactate.

13. The implantable osmotic delivery device of claim 10 , wherein the solvent is lauryl alcohol.

14. The implantable osmotic delivery device of claim 10 , wherein the suspending vehicle further comprises a lipid.

15. The implantable osmotic delivery device of claim 10 , wherein the particle formulation comprises the protein or peptide, sucrose, methionine, and citrate buffer in a weight ratio of 1:2:1:2.15.

16. The implantable osmotic delivery device of claim 10 , wherein particles of the formulation are made by spray-drying, lyophilization, or supercritical fluid processing.

17. The implantable osmotic delivery device of claim 10 , wherein the particle formulation comprises spray-dried particles.

18. The implantable osmotic delivery device of claim 17 , wherein the spray-dried particles comprise particles of about 1 μm to about 10 μm in diameter.

19. The implantable osmotic delivery device of claim 10 , wherein the osmotic agent is a tablet comprising NaCl.

20. The implantable osmotic delivery device of claim 19 , wherein the incompressible fluid additive comprises PEG.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2011
From: ELIAZ, ROM EZER; ZHANG, YUANPENG; ROHLOFF, CATHERINE MANYA; WEEKS, ERIC WILLIAM; JUNNARKAR, GUNJAN
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 026628/0839 →
Continuity (7)
Continuation 12655397 · Dec 29, 2009
Continuation 10988716 · Nov 15, 2004
Continuation In Part 12315194 · Nov 26, 2008
Continuation 10742730 · Dec 19, 2003
Provisional Application 60520605 · Nov 17, 2003
Provisional Application 60435180 · Dec 19, 2002
Related Publication 20110208168A1 · Aug 25, 2011